Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150µg of Nestorone and 15µg of Ethinyl Estradiol (150/15 NES/EE CVR)

Trial Profile

A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150µg of Nestorone and 15µg of Ethinyl Estradiol (150/15 NES/EE CVR)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Estradiol/elcometrine (Primary)
  • Indications Pregnancy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2018 According to a Food and Drug Administration media release, Based on the results of two pivotal studies (14506 and 22366 ), the U.S. Food and Drug Administration (FDA) has approved Annovera, which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.
    • 31 Jul 2018 According to a TherapeuticsMD, New Drug Application (NDA) for the one-year vaginal contraceptive system is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA's review of the NDA of August 17, 2018.
    • 22 Jun 2008 The expected completion date for this trial is now 1 Jun 2009 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top